Psychedelic research feels new to most people. It is not.
Scientists studied these compounds intensively for roughly two decades. Then the work stopped almost entirely. Decades later, it resumed.
Knowing that arc helps you read current headlines accurately. It also explains why the evidence base looks the way it does today.
The First Wave: 1940s to 1960s
Albert Hofmann synthesized LSD at Sandoz Laboratories in 1938. He discovered its effects five years later, in 1943.
Sandoz then distributed the compound to researchers worldwide. The company hoped clinicians would find psychiatric applications.
They tried. Researchers published roughly a thousand papers over the following two decades. Studies examined alcoholism, anxiety, depression, and end-of-life distress.
Psilocybin entered the picture separately. A 1957 magazine account of Mexican mushroom ceremonies brought the compound to Western attention. Sandoz began producing synthetic psilocybin shortly afterward.
Much of this early work looks weak by modern standards. Control groups were rare. Outcome measures were inconsistent. Researchers often reported enthusiasm rather than data.
Even so, the volume of interest was real. Psychedelics sat squarely inside mainstream psychiatry.
The Shutdown
Two forces ended the first wave.
First, some researchers abandoned scientific rigor. High-profile figures at Harvard blurred the line between study and advocacy. The resulting scandals damaged the field’s credibility.
Second, these compounds moved into broader culture. Political backlash followed quickly.
The Controlled Substances Act placed LSD and psilocybin in Schedule I in 1970. That classification declared no accepted medical use.
Funding disappeared. Approvals became nearly impossible. Consequently, human research effectively stopped for a generation.
The Slow Return
The pause was not permanent.
A small number of researchers pushed for approvals through the 1990s. Regulatory permission returned gradually. Studies remained tiny and poorly funded.
The picture shifted in the 2000s. Johns Hopkins published psilocybin research in 2006 that met modern methodological standards. Other universities followed.
Momentum built through the 2010s. Imperial College London, NYU, and other institutions launched trials. Funding improved. Peer-reviewed publication became routine.
The Current Moment
Recent years have produced significant regulatory movement, along with one significant setback.
The FDA rejected Lykos Therapeutics’ MDMA-assisted therapy application for PTSD in 2024. The agency pointed to functional unblinding as a central problem — participants could tell whether they received the active drug, which biased reported outcomes. nih + 2
That rejection reshaped the field. Several companies shifted toward studying the compounds as drugs rather than as therapy adjuncts.
Federal posture has since changed markedly. An executive order in April 2026 directed agencies to accelerate psychedelic research and regulatory review for serious mental illness. Days later, the FDA issued National Priority Vouchers to three programs: Compass Pathways for psilocybin in treatment-resistant depression, the Usona Institute for psilocybin in major depression, and Transcend Therapeutics for methylone in PTSD. Those vouchers compress a standard ten-to-twelve-month review into one or two months.The FDA also finalized its industry guidance on psychedelic clinical trials in July 2026 Medical Daily + 4
. A public hearing on therapeutic use followed in September 2026. Tech Times
Other countries moved earlier. Australian regulators have permitted authorized prescribers to use psilocybin for treatment-resistant depression and MDMA for PTSD since 2023. nih
What the History Suggests
Several lessons emerge from this arc.
Enthusiasm outran evidence once already. The first wave collapsed partly because advocacy replaced rigor. That pattern is worth watching for now.
Methodology remains genuinely hard. Blinding is the clearest example. Researchers have not solved it, and it complicates every efficacy claim.
Regulatory change moves faster than clinical knowledge. Legal access and proven safety are separate questions. Do not assume one implies the other.
The research is young. Sample sizes remain modest. Long-term follow-up data is thin. Honest providers acknowledge both facts.
Reading Headlines Carefully
Coverage of this field tends toward extremes. Some articles promise revolution. Others predict collapse.
A few habits help. Check whether a study used a control group. Note the sample size. Ask whether results held at follow-up. Distinguish regulatory news from clinical findings.
Careful reading serves you better than any single headline.
Questions About Your Own Situation
General research tells you what happens on average. It cannot tell you whether an approach fits you.
At Psychedelic Therapy Denver, we discuss the evidence honestly during consultations, including where it remains uncertain.